Point72 Asia (Singapore) Pte. Ltd. Moon Lake Immunotherapeutics Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 3,535 shares of MLTX stock, worth $45,141. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,535Holding current value
$45,141% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MLTX
# of Institutions
181Shares Held
38.5MCall Options Held
4.13MPut Options Held
1.51M-
Bvf Inc San Francisco, CA19.8MShares$252 Million7.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY2MShares$25.5 Million0.2% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.99MShares$25.5 Million2.28% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.7MShares$21.7 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.5MShares$19.2 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $472M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...